Notice of Interim Results

RNS Number : 5704Z

Life Science REIT PLC

15 September 2022

 

15 September 2022

LEI: 213800RG7JNX7K8F7525

Life Science REIT plc

("Life Science REIT" or the "Company")

Notice of Results for the six months ended 30 June 2022

Life Science REIT (AIM: LABS), the real estate investment trust focused on UK life science properties, is pleased to announce that it will report its interim results for the six months ended 30 June 2022 on Thursday 22 September 2022.

A n online meeting for analysts will be held at 9.30am on the morning of the results announcement and will be hosted by Ironstone Asset Management, the Company's Investment Adviser. To register attendance, or for further details, please contact [e-mail] .

FOR FURTHER INFORMATION, PLEASE CONTACT:

Ironstone Asset Management - Investment Adviser
Simon Farnsworth	via Buchanan below
Panmure Gordon - Nominated Adviser and Joint Corporate Broker	[phone]
Atholl Tweedie / Alex Collins / Philip Shields / Chloe Ponsonby
Jefferies International Limited - Joint Corporate Broker	[phone]
Tom Yeadon / Andrew Morris / Oliver Nott / Harry Randall
G10 Capital Limited - AIFM	[phone]
Verity Morgan-Jones / Paul Cowland
Buchanan - Financial PR	[phone]
Mark Court / Henry Wilson / Verity Parker [e-mail]

Notes to editors

Life Science REIT plc is a property business focused solely on the UK's growing life science sector, specifically targeting opportunities in the "Golden Triangle" research and development hubs of Oxford, Cambridge and London St Pancras. The Company's intention is to become the property provider of choice for life science companies in the UK, whilst enabling shareholders to gain exposure to a specific growth sector. 

The objective of the Company's investment policy is focused on capital growth, whilst also providing a growing level of income, by investing primarily in a diversified portfolio of properties that are leased, or intended to be leased, to occupiers operating in the life science sector in the UK. 

Life Science REIT joined the AIM market of the London Stock Exchange on 19 November 2021, having raised £350 million in its IPO. Its shares trade under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk

 

END

 

 

NORBKPBNPBKKOCD